Adesis is a U.S.-based chemistry CDMO that partners with pharmaceutical and biotechnology companies to accelerate the development of CNS therapeutics through advanced synthetic chemistry, process development, and manufacturing. We support programs from early discovery through process optimization and commercial manufacturing, providing the chemistry expertise needed to solve complex development challenges.

Our capabilities include custom synthesis, medicinal chemistry support, stable isotope labeling, deuterated compound synthesis, metabolite and impurity preparation, reference standards, critical starting materials (RSMs), key starting materials (KSMs), and scalable process development for complex small molecules. We work closely with clients to optimize synthetic routes, improve manufacturability, reduce technical risk, and ensure a reliable path from research to manufacturing.

Whether you're advancing a new CNS therapeutic or preparing for clinical and commercial manufacturing, we'd welcome the opportunity to discuss how Adesis can help accelerate your program with practical chemistry solutions and collaborative development expertise.